Search the Newsreel

Ascendis Pharma (NasdaqGS:ASND) Stock Turns Profitable As YORVIPATH Drives Growth

Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Misses Estimates By $0.68 EPS

Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says

Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of Yuviwel in achondroplasia is progressing well, RBC Capital Markets said in a Thursday note.According to the note, Yorvipath revenue rose to 252 million euros ($291.8 million) from Silver …

Ascendis Pharma A/S Q2 Earnings Call Highlights

Ascendis Pharma A/S reported strong Q2 2026 results, with total revenue more than doubling year-over-year due to increased demand for its TransCon-based therapies. Yorvipath and Yuviwel showed significant growth and early momentum, respectively, contributing to the company's positive financial outlook. Ascendis also outlined pipeline …

Ascendis Pharma Slides as Investors Weigh Strong Q2 Growth Against One-Time Profit Boost

Ascendis Pharma (ASND) posts Q2 2026 profit on revenue surge and PRV sale

Ascendis Pharma AS earnings beat by €1.32, revenue topped estimates

Ascendis Pharma (ASND) posts €836M H1 profit and redeems $575M converts

Ascendis Pharma Reports Second Quarter 2026 Financial Results

Ascendis Pharma announced strong financial results for Q2 2026, with total product revenue reaching €315 million, a 105% year-over-year increase, driven by YORVIPATH®, SKYTROFA®, and YUVIWEL®. The company reported a net profit of €207 million and significant pipeline advancements, including long-term data for YORVIPATH, …

Ascendis Pharma Reports More Than 220 U.S. YUVIWEL Enrollments

Ascendis Pharma A/S Q2 2026 Earnings Call Transcript

Ascendis Pharma A/S announced strong Q2 2026 financial results, with total revenue more than doubling year-over-year to €339 million, driven by robust demand for their TransCon products, YORVIPATH, YUVIWEL, and SKYTROFA. The company reiterated its long-term growth targets, including €5 billion in revenue by …

Ascendis Pharma (ASND) issues 15,060 staff warrants at $254.57 strike price

Ascendis Pharma A/S has granted 15,060 warrants to employees, with an exercise price of US $254.57 per share, matching the closing price on the grant date of August 11, 2026. These warrants vest over time, with 25% vesting after one year and the remainder …

Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today

Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past five years, achieving an average annual return of 17.21%. A $100 investment in ASND five years ago would now be worth $212.53, demonstrating the power of compounded returns. The article highlights the significant …

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275

Morgan Stanley has reiterated its Buy rating for Ascendis Pharma A/S (ASND.US) and maintained its target price at $275. This indicates a continued positive outlook from the investment bank regarding the company's stock performance.

(ASND) Volatility Zones as Tactical Triggers

This article analyzes Ascendis Pharma A/s (NASDAQ: ASND), highlighting a mid-channel oscillation pattern and a strong 27.6:1 risk-reward setup. It provides institutional trading strategies for various risk profiles, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report identifies positive …

Ascendis Pharma (ASND) Could Be 20% Undervalued Following Its Recent Pullback

Ascendis Pharma (ASND) has experienced a recent pullback, with its stock down about 9% over the past month. Despite this, a common valuation narrative suggests the company is 19.8% undervalued, with a fair value of $304.60 compared to its current share price of $244.20. …

Ascendis plans Aug. 13 webcast before U.S. markets open

Ascendis Pharma (Nasdaq: ASND) will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the U.S. market opens. The company will host a conference call and live webcast at 8:00 a.m. Eastern Time, with a …

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Pharma A/S announced it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before U.S. financial markets open. The company will also host a conference call and live webcast on the same day at …

Ascendis Pharma (ASND) reports new TransCon CNP achondroplasia trial data

Ascendis Pharma (ASND) has reported positive new data from its Phase 2 COACH trial for achondroplasia, demonstrating durable growth in children treated with a combination of TransCon CNP and TransCon hGH. The combination therapy achieved annualized growth velocity at or above the 97th percentile, …

Ascendis Announces COACH Week 78 Results and Provides

Ascendis Pharma announced positive 78-week results from its COACH trial for achondroplasia, showing durable, proportional growth with combination therapy (TransCon CNP + TransCon hGH). The company also provided an update on YUVIWEL (TransCon CNP) uptake in the U.S. and highlighted durable benefits from TransCon …

ASND Price Today: Ascendis Pharma A/S Stock Price, Quote & Chart | MEXC

This article provides current stock information for Ascendis Pharma A/S (ASND) on MEXC, detailing its live price, key market data like market cap and trading volume, and recent price performance. It also includes an FAQ section addressing common investor questions about the company's stock, …

Ascendis Pharma A/S

The article is a financial filing notification, specifically a Form 6K from Ascendis Pharma A/S, for April 8. It also includes general market data, news headlines, and stock performance figures, typical of a financial news platform.

ASND News & Events

This page provides a comprehensive overview of recent news, events, and price alerts related to Ascendis Pharma (ASND). It includes various news articles detailing clinical trial data releases, index inclusions, and financial results. The events section highlights analyst notes and new data presentations for …

ASND Stock News Today | Earnings, Events & Price Alerts

Ascendis Pharma A/S (ASND) Institutional Confidence

Ascendis Pharma A/S (ASND) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 111.42%, a slight decrease of 4.32% quarter-over-quarter. ETHSX is the largest institutional shareholder, holding 132.15K shares, which represents …

Ascendis Pharma A/S (ASND) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Ascendis Pharma A/S (ASND), highlighting its current valuation score of 7.87 within the Biotechnology & Medical Research industry. It notes the P/E ratio is 36.18, which is below its recent high but significantly above its recent low. …

Ascendis Pharma A/S ADR Unsponsored Brazilian Depositary Receipt Repr 0.0666 ADR

This page provides financial information for Ascendis Pharma A/S ADR (A1SN34) traded on BMFBOVESPA. It focuses on the "Price to book forward" metric and lists the company's trading status as "Market closed" with "No trades." The content is primarily a financial data page from …

Ascendis Pharma A/S (ASND) Expected to Release Quarterly Earnings on Thursday

Ascendis Pharma A/S $ASND Stock Holdings Reduced by Tri Locum Partners LP

Empowered Funds LLC Acquires 14,438 Shares of Ascendis Pharma A/S $ASND

Ascendis Pharma A/S (ASND) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Ascendis Pharma A/S (ASND), focusing on its price momentum, support and resistance levels, and various technical indicators. The stock's current price momentum score is 3.21, ranking it low in the Biotechnology & Medical Research industry, and it …

Ascendis Pharma A/S (ASND) Financial Health: Profitability & Balance Sheet Analysis

Ascendis Pharma A/S (ASND) has a current financial score of 8.41, ranking 45 out of 385 in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. The company's latest quarterly revenue surged by 153.66% year-over-year to $289.14 million, with …

Ascendis Pharma Number of Employees 2026 | Employee Count & Headcount Data

Ascendis Pharma A/S (NASDAQ: ASND) had 1,439 employees worldwide as of March 2026, marking a 49.3% growth since 2023. The company is actively hiring, with 186 job postings in 2026, and its workforce is primarily concentrated in Denmark, the United States, and Germany. The …